ABOS
Acumen Pharmaceuticals, Inc.
Key Financials
Net Income
$-121335000
↓ 18.6%
Operating Income
$-123832000
↓ 8.6%
Total Assets
$122.8M
↓ 48.6%
EPS (Diluted)
$-2.00
↓ 17.0%
Shareholders' Equity
$70.4M
↓ 61.3%
Total Liabilities
$52.4M
↓ 8.3%
Cash & Equivalents
$54.0M
↑ 51.5%
Long-term Debt
$22.4M
↓ 23.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 4/7/2026 | View on SEC |
| EFFECT | 4/1/2026 | View on SEC |
| 424B3 | 4/1/2026 | View on SEC |
| S-3 | 3/26/2026 | View on SEC |
| S-8 | 3/26/2026 | View on SEC |
| 10-K | 3/26/2026 | View on SEC |
| 8-K | 3/26/2026 | View on SEC |
| 4 | 3/18/2026 | View on SEC |
| SCHEDULE 13D/A | 3/17/2026 | View on SEC |
| 8-K | 3/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ABOS |
| Company Name | Acumen Pharmaceuticals, Inc. |
| CIK | 1576885 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-344-4190 |